Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
SLC29A1	2030	NITROBENZYLMERCAPTOPURINE RIBONUCLEOSIDE	CHEMBL418509	inhibitor	GuideToPharmacologyInteractions
SLC29A1	2030	ALCOHOL	CHEMBL545		NCI	15258586
SLC29A1	2030	FLUOROURACIL	CHEMBL185		PharmGKB
SLC29A1	2030	CYTARABINE	CHEMBL803		NCI	15632314
SLC29A1	2030	DILAZEP	CHEMBL126075	inhibitor	GuideToPharmacologyInteractions
SLC29A1	2030	DIPYRIDAMOLE	CHEMBL932	inhibitor	GuideToPharmacologyInteractions, ChemblInteractions
SLC29A1	2030	PENTAGASTRIN	CHEMBL1328	inhibitor	GuideToPharmacologyInteractions
SLC29A1	2030	TICAGRELOR	CHEMBL398435	inhibitor	GuideToPharmacologyInteractions
SLC29A1	2030	GEMCITABINE	CHEMBL888		CGI
SLC29A1	2030	TROGLITAZONE	CHEMBL408	inhibitor	DrugBank	15963471
SLC29A1	2030	DRAFLAZINE	CHEMBL1628717	inhibitor	GuideToPharmacologyInteractions
SLC29A1	2030	DICLOXACILLIN	CHEMBL893		GuideToPharmacologyInteractions
SLC29A1	2030	URIDINE	CHEMBL100259		NCI	10763851

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
SLC29A1	rs9394992	CT + TT	tipiracil hydrochloride	efficacy	yes	The SNP was tested for association alone and with three other SNPs after univariate and multivariate analysis in a training (N= 52, Japan) and testing cohorts (N = 127, Italy). Although it remained significantly associated with progression-free and overall survival in univariate and multivariate analysis in the training cohort, it was not significant in the testing cohort.	Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC.	28992563	1449146792
SLC29A1	rs3734703	A	cytarabine	efficacy	yes	Effect was measured by comparing allele frequency in patients achieving complete remission to those failing to achieve complete remission.	Allele A is associated with increased response to cytarabine in people with Leukemia, Myeloid, Acute as compared to allele C.	27422302	1448261958
SLC29A1	rs9394992	CC	gemcitabine	efficacy	no	Tumor response to therapy and progression free survival did not significantly differ between genotype groups.	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	20665488	981794238
SLC29A1	rs747199	GG	gemcitabine	metabolism/PK	no	Gemcitabine, dFdCTP, and dFdU plasma concentrations were measured before (5, 15, 30, 45 min) and after gemcitabine infusion (1, 1.25, 1.5, 2, 6, 24, 48, 72 hrs). Population pharmacokinetic analysis of gemcitabine and metabolites (dFdU, dFdCTP) were performed by non-linear mixed effects modeling. No association was found between rs747199 and metabolism of gemcitabine.	Genotype GG is not associated with metabolism of gemcitabine as compared to genotypes CC + CG.	24300978	1184174886
SLC29A1	rs324148	CC	gemcitabine	"efficacy","toxicity"	no	Tumor response to therapy, progression free survival, and risk of neutropenia development did not significantly differ between genotype groups.	Genotype CC is not associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes CT + TT.	20665488	981794226
SLC29A1	rs747199	G	gemcitabine	efficacy	no	This SNP is part of a two SNP haplotype with rs760370 A allele. Together they are associated with a significantly shorter overall survival, however results did not remain statistically significant in multivariate analysis. SNPs with an uncorrected p-value from univariate analysis were then included in a multivariate analysis and Bonferroni method was used to adjust for multiple hypotheses testing. The initially significant p-value did not remain significant in the multivariate analysis.	Allele G is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele C.	24361227	1184085972
SLC29A1	rs760370	GG	peginterferon alfa-2a	efficacy	yes	There was a significant association with more frequent RVR(rapid virological response) but not with SVR(sustained virological response) (50% vs. 17%). Subjects were coinfected with HIV. Patients were treated with ribavirin plus peginterferon alfa-2a OR peginterferon alfa-2b. SVR was ascertained at 24 weeks post-treatment.	Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG.	20812847	981481458
SLC29A1	rs760370	GG	gemcitabine	"efficacy","toxicity"	no	Patients with the GG genotype has worse tumor response to treatment with gemcitabine than patients with the AG or AA genotypes. However, progression free survival and risk of neutropenia development did not significantly differ between genotype groups. There were four SNPs in this study that, when taken together, affected progression free survival: rs183484, rs2072671, rs760370, and rs9937. Using patients with 0 or 1 variant as reference, patients with 2 variants had an increased HR of 1.79 (P = 0.004) and patients with 3-4 variants has an increased HR of 3.25 (P < 0.001). There were also two SNPs in this study that, when taken together, affected tumor response to therapy: rs2072671 and rs760370. Using patients with 0 variants as reference, patients with 1-2 variants had an increased OR of 3.40 (P = 0.004).	Genotype GG is associated with decreased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotypes AA + AG.	20665488	981794208
SLC29A1	rs760370	A	gemcitabine	efficacy	yes	This SNP is part of a two SNP haplotype with rs747199 G allele. Together they are associated with a significantly shorter overall survival, however the results did not remain significant in multivariate analysis. SNPs with an uncorrected p-value from univariate analysis were then included in a multivariate analysis and Bonferroni method was used to adjust for multiple hypotheses testing. The initially significant p-value did not remain significant in the multivariate analysis.	Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G.	24361227	1184086271
SLC29A1	rs760370	AG + GG	tipiracil hydrochloride	efficacy	yes	The G allele was tested for association alone and with two other SNPs after univariate and multivariate analysis in training (N= 52, Japan) and testing cohorts (N = 127, Italy). It was associated with improved progression-free and overall survival in the training and testing cohorts after univariate and multivariate analyses. When tested with other SNPs (rs2289669 G>A and rs316019 A>C) it was also associated with overall, but not progression-free survival.	Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA.	28992563	1449001814
SLC29A1	rs3778504	AA + AG	gemcitabine	efficacy	no	Associated with longer time to progression but this was not statistically significant after multivariate analysis. Stats corrected with the false-discovery rate for candidate SNPs and Bonferroni method (p<0.05 was considered significant).	Genotypes AA + AG are associated with increased response to gemcitabine in people with Pancreatic Neoplasms as compared to genotype GG.	22838950	981237781